Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)

Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Chida, Keigo, Kotani, Daisuke, Moriwaki, Toshikazu, Fukuoka, Shota, Masuishi, Toshiki, Takashima, Atsuo, Kumekawa, Yosuke, Kajiwara, Takeshi, Yamazaki, Kentaro, Komoda, Masato, Makiyama, Akitaka, Denda, Tadamichi, Hatachi, Yukimasa, Suto, Takeshi, Sugimoto, Naotoshi, Enomoto, Masanobu, Ishikawa, Toshiaki, Kashiwada, Tomomi, Ando, Koji, Yuki, Satoshi, Okita, Yoshihiro, Kusaba, Hitoshi, Sakai, Daisuke, Okamoto, Koichi, Tamura, Takao, Yamashita, Kimihiro, Gosho, Masahiko, Shimada, Yasuhiro
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7982575/
https://ncbi.nlm.nih.gov/pubmed/33763345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.576036
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados